NEW YORK (GenomeWeb) – Molecular diagnostics firm T2 Biosystems this week filed with the US Securities and Exchange Commission to sell up to $100 million of its common stock through one or more future offerings.

According to the filing, the company is also seeking SEC approval for certain undisclosed shareholders to sell up to $43 million of the company's common stock from time to time. T2 said that it would not receive any of the proceeds from the sale of these securities.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.